Skip to main content

Genomind: Cynthia Kilroy

Genomind, a company developing pharmacogenetic tests for mental health conditions, has appointed Cythia Kilroy as chief strategy and corporate development officer. She joins the company from Cognizant, where she held positions in the healthcare and health strategy groups. Kilroy has also previously worked for Optum, Huron Consulting Group, and her own firm, CCK Consulting.

Genomind has also appointed Stephen Saklad to its scientific advisory board. Saklad is a clinical professor of pharmacotherapy, and adjoint professor at the University of Texas School of Medicine; and director of the Psychiatric Pharmacy Program at the San Antonio State Hospital, Texas Department of State Health Services. He is an expert clinical pharmacologist with special interest in psychopharmacology, and holds a doctor of pharmacy degree from the University of Southern California.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.